Loading…
German-Dutch online pharmacy selling prescription and over-the-counter medicines and health products across Europe.
German-Dutch online pharmacy selling prescription and over-the-counter medicines and health products across Europe.
Sells medicines and health products shipped from central warehouses, with the non-prescription range carrying most revenue and prescriptions growing since Germany made electronic prescriptions mandatory in 2024. Germany is the largest market. The company is based in the Netherlands and was formerly named Shop Apotheke Europe.
In one line: A European Amazon Pharmacy/GoodRx hybrid.
Moat: narrow (scale, brand, regulatory licence). First-mover scale in German e-prescription market and pharmacy licences, but faces new entrants as e-Rx opens up.
Headquarters: Sevenum, Netherlands / Cologne, Germany · Founded: 2000 · Employees: 2,649
Size Redcare Pharmacy (RDC.DE) is a Germany Health Care company (Medical Distributors) with a market value of $1.63B, the 119th largest of 205 Germany companies the cockpit tracks. Shares closed at €70.55 on 6 Nov 2026.
Performance Over six months the shares gained 51.9%, against +1.8% for the median peer and +2.6% for the Germany market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 18.6% over the last twelve months (peer median +6.0%); the operating margin is 0.1% (peer median 3.2%).
Valuation It trades at 0.5× enterprise value to sales against a peer median of 0.5× (11th cheapest of 21).
Capital Return on invested capital runs 9.2 points below its cost of capital (9.5% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €3.34B | €2.94B | €2.37B | €1.80B | €1.20B |
| Revenue growth | — | +24% | +32% | +49% | — |
| Gross profit | €645M | €594M | €478M | €383M | €292M |
| EBITDA | €78.0M | €45.6M | €28.9M | €40.5M | -€15.3M |
| Net income | -€34.0M | -€37.7M | -€45.5M | -€12.0M | -€77.6M |
| Free cash flow | -€20.4M | -€56.3M | €11.4M | €51.8M | -€49.4M |
| Capital expenditure | €93.4M | €119M | €42.2M | €38.2M | €53.5M |
| Total debt | €354M | €416M | €278M | €275M | €241M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Redcare Pharmacy RDC.DE | $1.63B | +52% | +19% | 0% | 0.5× | n/a |
| Amazon AMZN | $2.80T | -5% | +15% | 13% | 3.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RDC.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.4% | +3.1% | 2nd lowest of 21 |
| 6-month return | +51.9% | +1.8% | 2nd highest of 21 |
| Distance from 52-week high | -11.7% | -15.3% | 7th highest of 21 |
| Revenue growth (TTM) | +18.6% | +6.0% | 2nd highest of 21 |
| Operating margin | 0.1% | 3.2% | 3rd lowest of 21 |
| EV / Sales | 0.5× | 0.5× | 11th cheapest of 21 |
| ROIC minus cost of capital | -9.2 pp | +1.9 pp | 2nd lowest of 21 |
| Net debt / EBITDA | 2.9× | -1.2× | 2nd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | 0.5× | n/a | n/a |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 0.1× | -7.4% | +5.1% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 0.2× | -14.7% | +7.6% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | 0.6× | -1.3% | +17.9% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 0.7× | -5.9% | +1.2% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 0.1× | -11.9% | +3.2% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 1.3× | -1.0% | +6.3% |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | 0.3× | n/a | n/a |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | 0.9× | n/a | n/a |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 1.3× | -1.3% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 0.4× | -9.5% | +6.0% |
| Hanmi Science 008930.KS | South Korea | $2.71B | +44% | +6% | 5% | 2.6× | 24.2% | +9.6% |
| Alfresa 2784.T | Japan | $2.79B | -3% | +5% | 1% | 0.1× | -9.1% | +3.5% |
| Shanghai Haohai Biological Technology 688366.SS | China | $946M | -24% | -9% | -2% | 2.0× | 18.9% | +13.2% |
| Asker Healthcare ASKER.ST | Sweden | $2.98B | -5% | +12% | 7% | 1.6× | 1.2% | +12.7% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 1.2× | 21.8% | +29.9% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.20B | +5% | +9% | 4% | 0.5× | n/a | n/a |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 0.3× | 5.0% | +8.1% |
| MEDIPAL 7459.T | Japan | $3.67B | +14% | +4% | 1% | 0.1× | -7.4% | +3.5% |
| Amplifon AMP.MI | Italy | $3.72B | +13% | 0% | 9% | 1.8× | 9.5% | +9.8% |
| Jointown Pharmaceutical 600998.SS | China | $3.96B | +1% | +9% | 2% | 0.4× | 0.1% | +7.8% |